a Workshop
Friday, 07/23/2021, 9:00 am to 12:00 pm. ARCHIVED EVENT
FDA approves $56,000 treatment for Alzheimer’s with Questionable Efficacy – What happens Next?
Co-hosted by the Hopkins Business of Health Initiative (HBHI) and the Hopkins Economics of Alzheimer’s Disease and Services Center (HEADS Center).
Registration Required.
On June 7, 2021 the FDA approved a new treatment for Alzheimer’s, yet there remains a contentious debate about whether the drug is effective. While this debate rages, millions of people may be eligible for this drug costing $56,000/year which, in one stroke, might double the nation’s spending on prescription drugs. What happens next? The Hopkins Business of Health Initiative and the Hopkins Economics of Alzheimer’s Disease and Services Center have assembled experts to lay the groundwork to inform action steps that would best leverage the opportunities and limit the challenges tied to the approval of aducanumab.
Moderator: Dan Gorenstein, Executive Producer and Host of Tradeoffs